

# TABLE OF CONTENTS

November 20, 2006

No. 2017

## BUSINESS

- 1 CMIC Aims at Becoming Pharmaceutical Value Creator
- 3 Takeda Seeking Acquisition Opportunities in Specific Fields
  - Inappropriate Vendor Selection Process Discovered
  - Overseas Sales of Ethical Drugs Drive Growth
- 4 Astellas to Embark on Asian Studies
  - Astellas Goes to Court to Confirm Term of Atorvastatin License Agreement
  - Lawsuit Is Just to Confirm Term of Agreement: President Nogimori
  - Sales Up, Profits Hit by Licensing Costs
- 5 Daiichi Sankyo: Olmetec/Benicar Drove Increase in Sales
  - Daiichi Sankyo in Final Dash to Full Integration Next April
- 6 Dainippon Sumitomo Preparing Plan for Overseas Business Expansion
  - Loss of Sales of ¥30.2 Bil. Due to End of Tie-ups
- 7 Taisho: Sales of OTC, Ethical Drugs Down in 1st Half
  - Aiming for Sales of ¥290 Bil. in FY2012
- 8 Shionogi: Sluggish Sales of Antibiotics Hurt 1st-Half Results
  - Expanded Marketing of Crestor to Drive Growth in Full-year Sales
- 8 Tanabe Seiyaku to Announce Generic Business Plan by Next March
  - Sales of Ethical Drugs Up 2.4%
- 9 Ono: Generic Competition Impacts Sales of Major Products
- 10 Midterm Plan to Focus on Improving Profit Structure: Santen
  - Overseas Business Drives Growth in Sales
- 11 Meiji Seika Licenses Penem, Antithrombotic Agents to US Companies
- 11 **BUSINESS NEWS IN BRIEF**
  - MPC Obtains Worldwide License for Kremezin from Kureha
  - Kobayashi Sells All Shares of Its US Subsidiaries
  - Banyu to Change Name to Merck-Banyu
  - Yasuchika Hasegawa Appointed Next President of OPMA
  - Three New Member Companies: OPMA
- 12 **TOPICS**
  - Henry McKinnell Decorated with Grand

Cordon: Pfizer Japan

- 12 **Survey**
  - Information Disclosure Key to Better Industry Image in Japan

## R&D

- 13 7th Kitasato University-Harvard School of Public Health Symposium
  - Focus on Critical Path Opportunities in Japan
  - New Assessment Methods Urgently Needed: Dr J. Woodcock
  - Japanese Version of Critical Path Proposed by Prof. Imura
  - Japanese Version of Critical Path Highly Interesting Topic: Mr Nakagaki
  - Fees Paid Even to Facilities with No Subjects Enrolled: Pfizer's Dr Shimatani
  - Japan Should Participate in More Global and Asian Studies
  - Flexible Reviews Required to Strengthen Int'l Competitiveness: Dr Harada
- 15 **R&D NEWS IN BRIEF**
  - AnGes MG Starts PII Study of NF-kB Decoy Oligo for Atopic Dermatitis
  - Trial of VM202RY for Ischemic Heart Disease to Start in Korea: Takara Bio
  - Oncolys BioPharma Starts PI Trial of Telomelysin in the US
  - Telomelysin Patented in Japan
  - Development of TU-025 to Be Delayed in US: Tsumura

## COMMENTARY

- 16 **Maurer's Healthcare Insight (81)**
  - Feedback Is My Nutrition: P. Reed Maurer

## NEW PRODUCTS

- 17 **NEW PRODUCTS**
  - Alcon Japan: Vegamox Ophthalmic Solution 0.5%
  - Biogen Idec Japan: Avonex Syringe for IM Injection

## MEDICAL DEVICES

- 18 Medtronic Opens Training Center
- 18 **MEDICAL DEVICE NEWS IN BRIEF**
  - MBL: MESACUP CCP Test and MESACUP BP180 Test
  - Kobayashi Acquires eVent of Ireland
  - Olympus: Medical Business Sales UP 12.5%